Pharmacodynamics and Drug–Receptor Interactions: Integrating PK/PD Modeling with Modern Drug Development

Year : 2026 | Volume : 16 | 02 | Page :
    By

    Aayush K. Ramraje,

  • Vilas K. Patil,

  • Avinash V. Kapure,

  • Dhiraj R. Girase,

  • Akshata M. Girase,

  • Bhupendra M. Mahale,

  • Ghanshyam M. Chavan,

  1. Research Scholar, Department of Pharmacy, Dr. Babasaheb Ambedkar Technological University Lonere, Raigad, Maharashtra, SVS’s Dadasaheb Rawal Pharmacy College, Maharashtra, India
  2. Research Scholar, Department of Pharmacy, Dr. Babasaheb Ambedkar Technological University Lonere, Raigad, Maharashtra, SVS’s Dadasaheb Rawal Pharmacy College, Maharashtra, India
  3. Research Scholar, Department of Pharmacy, Dr. Babasaheb Ambedkar Technological University Lonere, Raigad, Maharashtra, SVS’s Dadasaheb Rawal Pharmacy College, Maharashtra, India
  4. Research Scholar, Department of Pharmacy, Dr. Babasaheb Ambedkar Technological University Lonere, Raigad, Maharashtra, SVS’s Dadasaheb Rawal Pharmacy College, Maharashtra, India
  5. Assistant Professor, Department of Pharmaceutical Quality Assurance, Babasaheb Ambedkar Technological UniversityDepartment of Pharmaceutical Quality Assurance, Babasaheb Ambedkar Technological University, Maharashtra, India
  6. Assistant Professor, Department of Pharmaceutics, Dr. Babasaheb Ambedkar Technological University, Maharashtra, India
  7. Principal, SVS’s Dadasaheb Rawal Pharmacy College Mandal, Maharashtra, India

Abstract

Understanding drug action requires an integrated perspective of pharmacodynamics and pharmacokinetics, which together determine therapeutic efficacy and safety. This review provides a comprehensive overview of the mechanisms underlying drug action, with particular emphasis on drug–receptor interactions and their role in modulating physiological responses. Drugs exert their effects primarily through interactions with specific biological targets, including receptors, enzymes, ion channels, and transporters, resulting in a spectrum of desired and adverse outcomes. Fundamental pharmacodynamic principles such as receptor affinity, intrinsic activity, dose–response relationships, and therapeutic window are discussed in the context of clinical relevance. Recent advances in pharmacokinetic–pharmacodynamic (PK/PD) modeling have transformed drug development by enabling a more predictive and mechanistic understanding of drug behavior. Approaches such as physiologically based pharmacokinetic (PBPK) modeling, population-based analyses, and quantitative systems pharmacology (QSP) have improved dose optimization and facilitated precision medicine strategies. In addition, structure–activity relationship (SAR) and quantitative SAR (QSAR) methodologies continue to play a pivotal role in rational drug design and lead optimization. The review also examines key receptor-mediated signaling pathways, including G protein-coupled receptors, ion channels, enzyme-linked receptors, and nuclear receptors, highlighting their significance in drug response variability. Challenges such as interindividual differences, adverse drug reactions, and drug resistance are critically addressed. Collectively, these insights underscore the importance of integrating mechanistic pharmacology with emerging computational tools to enhance drug discovery and optimize therapeutic outcomes.

Keywords: Pharmacodynamics (PD), Drug metabolism ADME, Drug development, Systems pharmacology, drugs interaction, biochemical effects.

How to cite this article:
Aayush K. Ramraje, Vilas K. Patil, Avinash V. Kapure, Dhiraj R. Girase, Akshata M. Girase, Bhupendra M. Mahale, Ghanshyam M. Chavan. Pharmacodynamics and Drug–Receptor Interactions: Integrating PK/PD Modeling with Modern Drug Development. Research and Reviews: A Journal of Pharmacology. 2026; 16(02):-.
How to cite this URL:
Aayush K. Ramraje, Vilas K. Patil, Avinash V. Kapure, Dhiraj R. Girase, Akshata M. Girase, Bhupendra M. Mahale, Ghanshyam M. Chavan. Pharmacodynamics and Drug–Receptor Interactions: Integrating PK/PD Modeling with Modern Drug Development. Research and Reviews: A Journal of Pharmacology. 2026; 16(02):-. Available from: https://journals.stmjournals.com/rrjop/article=2026/view=245717


References

1. Anziano RJ, Milligan PA (2021) Model informed drug development: Collaboration through a common framework. Clin Pharmacol Ther. 110(5):1165-1167
2. Zvirblis P, Ellin RI (1976) Acute systemic toxicity of pure dimercaprol and trimercaptopropane. Toxicol Appl Pharmacol. 36(2):297-9.
3. Herrington DM. Role of estrogen receptor-a in pharmacogenetics of estrogen action. Curr Opin Lipidol 2003; 14:145-150.
4. Gao, W., and Jusko, W. J. (2012). Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab. Dispos. 40, 990–997. doi: 10.1124/dmd.111.042291
5. Gabrielsson, J., Dolgos, H., Gillberg, P. G., Bredberg, U., Benthem, B., and Duker, G. (2009). Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov. Today 14, 358–372. doi: 10.1016/j.drudis.2008.12.011
6. Danhof, M., de Lange, E. C. M., Pasqua, O. E. D., Ploeger, B. A., and Voskuyl, R. A. (2008). Mechanism based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29, 486–191. doi: 10.1016/j.tips.2008.01.007
7. Colburn, W. A. (2003). Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 43, 429–341. doi: 10.1177/0091270003252480.
8. Pattanaik S, Patil AN, Kumaravel J, Gaurav P. Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices. Front Oncol. 2022; 12:1015200
9. Agema BC, van Leeuwen RWF, Mathijssen RHJ, Koolen SLW. Barriers and facilitators for bringing model-informed precision dosing to the patient’s bedside: A systematic review. Clin Pharmacol Ther. 2023;114(1):44-57.
10. Huitema ADR, van Erp NP, Mathijssen RHJ, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: A prospective multicenter study. Ann Oncol. 2022;33(10):1071-1082.
11. Van Dongen MGJ, de Vries N, Dreesen E, et al. Precision dosing of targeted therapies: Ready for clinical implementation? Clin Pharmacokinet. 2023;62(1):1-12
12. Minichmayr I, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: State of the art and future perspectives. Adv Drug Deliv Rev. 2024; 215:115421
13. . Agema BC, Koolen SLW, Mathijssen RHJ. Model-informed development of a cost-saving dosing regimen for Sacituzumab Govitecan. Target Oncol. 2024; 19:789-796.
14. Cotsapas C, Hafler DA. Immune-mediated disease genetics, the shared basis of pathogenesis. Trends in Immunology. 34, 22-26 (2013).
15. Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008 Dec;22(6):633-48. [PubMed: 19049668]
16. Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J. 2008 Dec;10(4):537-51. [PMC free article: PMC2628209] [PubMed: 18989788]
17. Cahill CM, Walwyn W, Taylor AMW, Pradhan AAA, Evans CJ. Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation. Trends Pharmacol Sci. 2016 Nov;37(11):963-976. [PMC free article: PMC5240843] [PubMed: 27670390]
18. Ramamoorthy S, Cidlowski JA. Corticosteroids: Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii. [PMC free article: PMC4662771] [PubMed: 26611548]
19. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI. Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33. [PubMed: 16571968]
20. Dudek, Arkadiusz Z.; Arodz, Tomasz; Gálvez, Jorge. Computational methods in developing quantitative structure-activity relationships (QSAR): A review. Comb. Chem. High. Throughput Screen. 2006 Mar; 9(3):213–228. [PubMed: 16533155]
21. Winkler, David A. The role of quantitative structure–activity relationships (QSAR) in biomolecular discovery. Brief. Bioinform. 2002 Mar; 3(1):73–86. [PubMed: 12002226]
22. Zvinavashe E, Albertinka JM, Rietjens IMCM. Promises and pitfalls of quantitative structureactivity relationship approaches for predicting metabolism and toxicity. Chem. Res. Toxicol. 2008; 21(12): 2229–2236. [PubMed: 19548346]
23. Banerjee, Ashutosh; Schepmann, Dirk; Köhler, Jens; Würthwein, Ernst-Ulrich; Wünsch, Bernhard. Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists. Bioorg. Med. Chem. 2010 Nov; 18(22):7855–7867. [PubMed: 20965735]
24. Breiman L. Statistical modeling: Two cultures. Stat. Sci. 2001; 16:199–231.
25. Brown, Nathan; Lewis, Richard A. Exploiting QSAR methods in lead optimization. Curr. Opin. Drug Discov. Devel. 2006; 9(4):419–424.
26. Lajiness, MS. QSAR: Rational Approaches to the Design of Bioactive Compounds. Netherlands: Escom, Leiden; 1991. p. 201-204.chapter Evaluation of the Performance of Dissimilarity Selection Methodology
27. Maggiora, Gerald M. On outliers and activity cliffs–wh
28. Shanmugasundaram, V.; Maggiora, GM. CINF-032. 222nd ACS National Meeting, Chicago, IL, United States. Washington, DC: American Chemical Society; 2001. Characterizing property and activity landscapes using an information-theoretic approach.
29. Austin CP, Brady LS, Insel TR, Collins FS. NIH molecular libraries initiative. Science. 2004; 306:1138–1139. [PubMed: 15542455]
30. von Korff M, Sander T. Toxicity-indicating structural patterns. J. Chem. Inf. Model. 2006; 46:536– 544. [PubMed: 16562981]
31. Agrafiotis, Dimitris K.; Wiener, John JM. Scaffold explorer: An interactive tool for organizing and mining structure-activity data spanning multiple chemotypes. J. Med. Chem. 2010 Jul; 53(13): 5002–5011. [PubMed: 20524668]
32. Wetzel, Stefan; Klein, Karsten; Renner, Steffen; Rauh, Daniel; Oprea, Tudor I.; Mutzel, Petra; Waldmann, Herbert. Interactive exploration of chemical space with Scaffold Hunter. Nat. Chem. Biol. 2009 Aug; 5(8):581–583. [PubMed: 19561620]
33. Leggat PA. Occupational hygiene practices of dentists in southern Thailand. International Dental Journal. 51, 11-16(2001).
34. Angum, Fariha, Khan. The Prevalence of Autoimmune Disorders in Women, A Narrative Revi
35. Cotsapas C, Hafler DA. Immune-mediated disease genetics, the shared basis of pathogenesis. Trends in Immunology. 34, 22-26 (2013).
36. Kant AK. Dietary patterns and health outcomes. J Am Diet Assoc.104,615-635 (2004).
37. Esfahani A, Wong J MW, Truan J et al. Health fects of mixed fruit and vegetable concentrates: a systematic review of the clinical interventions. J Am Coll Nutr.30, 285-294(2011).
38. Angum, Fariha, Khan. The Prevalence of Autoimmune Disorders in Women, A Narrative Review.
39. Kou Qin, Chunmin Dong, Guangyu Wu and Nevin A Lambert (August 2011). “Inactive-state preassembly of Gq-coupled receptors and Gqheterotrimers”. Nature Chemical Biology. 7 (11): 740–747.
40. Purves, Dale, George J. Augustine, David Fitzpatrick, William C. Hall, Anthony-Samuel LaMantia, James O. McNamara, and Leonard E. White (2008). Neuroscience. 4th ed. Sinauer Associates. pp. 156–7.
41. Cascio M (2004). “Structure and function of the glycine receptor and related nicotinicoid receptors”. J. Biol. Chem. 279 (19): 19383–6
42. The Top Prescription Drugs of 2012 Globally: Biologics Dominate, But Small Molecule CNS Drugs Hold on to Top Spots” (PDF). ACS Chemical Neuroscience. Retrieved 2016-02-03
43. King N, Hittinger CT, Carroll SB (Jul 2003). “Evolution of key cell signaling and adhesion protein families predates animal origins”. Science. 301 (5631): 361–3..
44. Filmore D (2004). “It’s a GPCR world”. Modern Drug Discovery. American Chemical Society. 2004 (November): 24–28, [ Overington JP, Al-Lazikani B, Hopkins AL (Dec 2006). “How many drug targets are there?”. Nature Reviews. Drug Discovery. 5 (12): 993–6
45. Gilman AG (1987). “G proteins: transducers of receptor-generated signals”. Annual Review of Biochemistry. 56 (1): 615–49.
46. Wettschureck N, Offermanns S (Oct 2005). “Mammalian G proteins and their cell type specific functions”. Physiological Reviews. 85 (4): 1159–204.
47. Wettschureck N, Offermanns S (Oct 2005). “Mammalian G proteins and their cell type specific functions”. Physiological Reviews. 85 (4): 1159–204.
48. Qin K, Dong C, Wu G, Lambert NA (Oct 2011). “Inactive-state preassembly of G(q)-coupled receptors and G(q) heterotrimers”. Nature Chemical Biology. 7 (10): 740–7.
49. Wettschureck N, Offermanns S (Oct 2005). “Mammalian G proteins and their cell type specific functions”. Physiological Reviews. 85 (4): 1159–204.
50. Schlessinger J (Nov 1988). “Signal transduction by allosteric receptor oligomerization”. Trends in Biochemical Sciences. 13 (11): 443–7.
51. Li E, Hristova K (May 2006). “Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies”. Biochemistry. 45 (20): 6241–51.
52. Li E, Hristova K (May 2006). “Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies”. Biochemistry. 45 (20): 6241–51.
53. Roskoski R (Jun 2004). “The ErbB/HER receptor protein-tyrosine kinases and cancer”. Biochemical and Biophysical Research Communications. 319 (1): 1–11.
54. Igaz, P., Toth, S. and Falus, A. (2001). Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm. Res. 50, 435-441
55. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28:851–70.
56. Directive E. Directive 2011/62 – Amendment of Directive 2001/83/EC on the EC code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products; 2010. Available from: https://www. eumonitor.eu/9353000/1/j4nvk6yhcbpeywk_j9vvik7m1c3gyxp/ vitgbgj5kqzk#:~:text=Directive%202001/83/EC%20was,marketing% 20authorisations%20under%20certain%20circumstances.
57. . Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008;65:573–82
58. Coleman JJ, Ferner RE, Evans SJ. Monitoring for adverse drug reactions. Br J Clin Pharmacol. 2006;61:371–9.
59. Joshi SR, Sapatnekar SM. The importance of pharmacovigilance. Geneva: World Health Organization, Pharmacovigilance in India: how safe are the new drugs? How sure are we? J Assoc Physicians Ind. 2008;56(8):933–4
60. Craig A. Umscheid, MD, MSCE1,4, David J. Margolis, MD, PhD, MSCE2,5, and Craig E. Grossman, A reviw on “key concept of of clinical trials
61. Craig A. Umscheid, MD, MSCE1,4, David J. Margolis, MD, PhD, MSCE2,5, and Craig E. Grossman, A reviw on “key concept of of clinical trials.
62. Craig A. Umscheid, MD, MSCE1,4, David J. Margolis, MD, PhD, MSCE2,5, and Craig E. Grossman, A reviw on “key concept of of clinical trials.
63. Craig A. Umscheid, MD, MSCE1,4, David J. Margolis, MD, PhD, MSCE2,5, and Craig E. Grossman, A reviw on “key concept of of clinical trials
64. Different clinical trials on web site: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/types-of-clinical-trials
65. Graham A. colditz and Philip R. taylor A review on “prevention trials their place in how we understand the value of prevention strategies”
66. Different clinical trials on web site: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/types-of-clinical-trials
67. Different clinical trials on web site: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/types-of-clinical-trials
68. Different clinical trials on web site: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/types-of-clinical-trials
69. Role And Responsibilities of clinica trials on web site: https://www.viccompcancerctr.org/what-we-do/research-development/clinical-trials-expansion/investigator-initiated-trials/roles-and-responsibilities/clinical-trials-team/

Ahead of Print Subscription Review Article
Volume 16
02
Received 07/05/2026
Accepted 01/06/2026
Published 02/06/2026
Publication Time 26 Days
25

Login


My IP

PlumX Metrics